The effect of dabigatran on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples

Pathology

Volumn 47, Issue 4, 2015, Pages 355-364

  Bonar, Roslyn ^a   Favaloro, Emmanuel J ^b   Mohammed, Soma ^b   pasalic, Leonardo ^b   Sioufi, John ^a   Marsden, Katherine ^c  

^a RCPAQAP Haematology   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c ROYAL HOBART HOSPITAL   (Australia)

Author keywords

Anticoagulants; coagulation; dabigatran; haemostasis; laboratory testing

Indexed keywords

ANTITHROMBIN; DABIGATRAN;

BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECTS; DRUG MONITORING; HUMAN; IN VITRO STUDY; PROCEDURES;

ANTITHROMBINS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DABIGATRAN; DRUG MONITORING; HUMANS; IN VITRO TECHNIQUES;

EID: 84978661408     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0000000000000252     Document Type: Article

References (26)

1. 1. Favaloro, E.J., Lippi, G., Koutts, J., Laboratory testing of anticoagulants – the present and the future. Pathology 43 (2011), 682–692.
2. 2. Lippi, G., Franchini, M., Favaloro, E.J., Pharmacogenetics of vitamin K antagonists: useful or hype?. Clin Chem Lab Med 47 (2009), 503–515.
3. 3. Salmela, B., Joutsi-Korhonen, L., Armstrong, E., Lassila, R., Active online assessment of patients using new oral anticoagulants: bleeding risk, compliance, and coagulation analysis. Semin Thromb Hemost 38 (2012), 23–30.
4. 4. Di Minno, A., Spadarella, G., Prisco, D., Franchini, M., Lupoli, R., Di Minno, M.N., Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost 39 (2013), 840–846.
5. 5. Favaloro, E.J., Lippi, G., The new oral anticoagulants and the future of haemostasis laboratory testing. Biochemia Medica 22 (2012), 329–341.
6. 6. Lippi, G., Ardissino, D., Quintavalla, R., Cervellin, G., Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests. J Thromb Thrombolysis 38 (2014), 269–274.
7. 7. Rojas-Hernandez, M.D., Garcia, D.A., The novel oral anticoagulants. Semin Thromb Hemost 39 (2013), 117–126.
8. 8. Schulman, S., Majeed, A., The oral thrombin inhibitor dabigatran: strengths and weaknesses. Semin Thromb Hemost 38 (2012), 7–15.
9. 9. Favaloro, E., Bonar, R., Butler, J., Marsden, K., Laboratory testing for the new oral anticoagulants in Australia and New Zealand: A review of current practice. Pathology 45 (2013), 435–437.
10. 10. van Ryn, J., Stangier, J., Haertter, S., et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103 (2010), 1116–1127.
11. 11. Baglin, T., The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 1:Suppl 1 (2013), 122–128.
12. 12. Halbmayer, W., Weigel, G., Quehenberger, P., et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med 50 (2012), 1601–1605.
13. 13. Douxfils, J., Mullier, F., Robert, S., Chatelain, C., Chatelain, B., Dogné, J.M., Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107 (2012), 985–997.
14. 14. Harenberg, J., Giese, C., Marx, S., Krämer, R., Determination of dabigatran in human plasma samples. Semin Thromb Hemost 38 (2012), 16–22.
15. 15. Gosselin, R., Hawes, E., Moll, S., Adcock, D., Performance of various laboratory assays in the measurement of dabigatran in patients receiving therapeutic doses. Am J Clin Pathol 141 (2014), 262–267.
16. 16. Adcock, D., Gosselin, R., Kitchen, S., Dwyre, D., The effect of dabigatran on select speciality coagulation assays. Am J Clin Pathol 139 (2013), 102–109.
17. 17. Eikelboom, J., Weitz, J., Dabigatran monitoring made simple?. Thromb Haemost 110 (2013), 308–315.
18. 18. Mani, H., Kasper, A., Lindhoff-Last, E., Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Haemost 36 (2013), 187–194.
19. 19. Stangier, J., Feuring, M., Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23 (2012), 138–143.
20. 20. Tripodi, A., The laboratory and the direct oral anticoagulants. Blood 121 (2013), 4032–4035.
21. 21. Tripodi, A., Result expression for tests used to measure the anticoagulant effect of the new anticoagulants. Thromb J, 11, 2013, 912.
22. 22. Brunetti, L., Bandell, F., Dabigatran: is there a role for coagulation assays in guiding therapy?. Ann Pharmacol 47 (2013), 828–840.
23. 23. Douxfils, J., Dogne, J.M., Mullier, F., et al. Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost 110 (2013), 543–549.
24. 24. Lippi, G., Favaloro, E.J., Recent guidelines and recommendations for laboratory assessment of the direct or non-vitamin K antagonist oral anticoagulants (DOACs): Is there consensus?. Clin Chem Lab Med 53 (2015), 185–197.
25. 25. Tran, H., Joseph, J., Young, L., et al. New oral anticoagulants – a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Intern Med J 44 (2014), 525–536.
26. 26. Tsutsumi, Y., Shimono, J., Ohhigashi, H., Ito, S., Shiratori, S., Teshima, T., Analysis of the influence of dabigatran on coagulation factors and inhibitors. Int J Lab Hematol 37 (2015), 225–230.